REFERENCES:
1. Xanthopoulos A, Triposkiadis F, Starling RC. Care for patients with
ventricular assist devices and suspected COVID-19 infection. Eur J Heart
Fail. 2020 Jun;22(6):937-940.
2. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center
for Disease Control and Prevention . The Epidemiological characteristics
of an outbreak of 2019 novel coronavirus diseases (COVID‐19) in
China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145‐151.
3. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting
characteristics, comorbidities, and outcomes among 5700 patients
hospitalized with COVID‐19 in the New York city area. JAMA.
2020;323(20):2052‐2059.
4. Clerkin K.J., Fried J.A., Raikhelkar J. Coronavirus disease 2019
(COVID-19) and cardiovascular
disease. Circulation. 2020;141:1648–1655.
5. Zhou F., Yu T., Du R. Clinical course and risk factors for mortality
of adult inpatients with COVID-19 in Wuhan, China: a retrospective
cohort study. Lancet. 2020;395:1054–1062.
6. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu
X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B.
Clinical course and risk factors for mortality of adult inpatients with
COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar
28;395(10229):1054-1062.
7. Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the
cardiovascular system: implications for risk assessment, diagnosis, and
treatment options. Cardiovasc Res. 2020;116(10):1666-1687.
8. Epidemiology Working Group for NCIP Epidemic Response. The
epidemiological characteristics of an outbreak of 2019 novel coronavirus
diseases (COVID-19) in China. Chin J Epidemiol 2020;41:145–151.
9. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T,
Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA,
Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2
and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr
16;181(2):271-280.
10. Bairey Merz CN, Pepine CJ, Shimokawa H, Berry C. Treatment of
coronary microvascular dysfunction. Cardiovasc Res. 2020 Mar
1;116(4):856-870.
11. Murphy S.P., Kakkar R., McCarthy C.P., Januzzi J.L. Inflammation in
heart failure. J Am Coll Cardiol. 2020;75:1324–1340.
12. Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the
cardiovascular system: acute and long-term implications. Eur Heart J.
2020 May 14;41(19):1798-1800.
13. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai
G, Brown TS, Der Nigoghossian C, Zidar DA, Haythe J, Brodie D, Beckman
JA, Kirtane AJ, Stone GW, Krumholz HM, Parikh SA. Cardiovascular
Considerations for Patients, Health Care Workers, and Health Systems
During the COVID-19 Pandemic. J Am Coll Cardiol. 2020 May
12;75(18):2352-2371.
14. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects
of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol.
2020 Jul 1;5(7):831-840.
15. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With
Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA
Cardiol. 2020;5(7):802–810.
16. Moloney E.D., Evans T.W. Pathophysiology and pharmacological
treatment of pulmonary hypertension in acute respiratory distress
syndrome. Eur Respir J. 2003;21:720–727.
17. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z,
Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138
Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in
Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069.
18. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for
mortality of adult inpatients with COVID-19 in Wuhan, China: a
retrospective cohort study. Lancet 2020;395:1054-62.
19. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, Lee M.
Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19
in Washington State. JAMA. 2020 Apr 28;323(16):1612-1614.
20. Moss N., Rakita V., Lala A. Hemodynamic response to exercise in
patients supported by continuous flow left ventricular assist
devices. J Am Coll Cardiol HF. 2020;8:291–301.
21. Lang C.C., Agostoni P., Mancini D.M. Prognostic significance and
measurement of exercise-derived hemodynamic variables in patients with
heart failure. J Card Fail. 2007;13:672–679.
22. Bikdeli B., Madhavan M.V., Jimenez D. COVID-19 and thrombotic or
thromboembolic disease: implications for prevention, antithrombotic
therapy, and follow-up: JACC State-of-the-Art Review. J Am Coll
Cardiol. 2020;75:2950–2973.
23. Poissy J, Goutay J, Caplan M, Parmentier E, Duburcq T, Lassalle F,
Jeanpierre E, Rauch A, Labreuche J, Susen S; Lille ICU Haemostasis
COVID-19 Group. Pulmonary Embolism in Patients With COVID-19: Awareness
of an Increased Prevalence. Circulation. 2020 Jul 14;142(2):184-186.
24. 21. Extracorporeal Life Support Organization. Extracorporeal Life
Support Organization (ELSO) Guidelines for Adult Cardiac Failure
[Internet]. Available at:
https://www.elso.org/Portals/0/IGD/Archive/FileManager/
e76ef78eabcusersshyerdocumentselsoguidelinesforadultcardiacfailure1.3.
pdf. Accessed March 20, 2020.
25. Bartlett RH, Ogino MT, Brodie D, et al. Initial ELSO Guidance
Document: ECMO for COVID-19 Patients with Severe Cardiopulmonary
Failure. ASAIO J. 2020;66(5):472-474.
26. Laboratory abnormalities in patients with COVID-2019 infection.
Lippi G, Plebani M. Clin Chem Lab Med. 2020;58:1131–1134.
27. Schmidt M, Burrell A, Roberts L, et al. Predicting survival after
ECMO for refractory cardiogenic shock: the survival after
veno-arterial-ECMO (SAVE)-score. Eur Heart J 2015;36:2246-56.
28. MacLaren G, Fisher D, Brodie D. Preparing for the Most Critically
Ill Patients With COVID-19: The Potential Role of Extracorporeal
Membrane Oxygenation. JAMA. 2020 Apr 7;323(13):1245-1246.
29. Bassi GL, Suen J, Fraser J. Extracorporeal membrane oxygenation for
2019 novel coronavirus acute respiratory disease (ECMOCARD) Study
[Internet]. Available at: https://www.elso.org/Portals/0/Files/
ECMOCard/2019nCOv ECMO 03.17.20.pdf. Accessed March 20, 2020.
30. DeFilippis E.M., Farr M.A., Givertz M.M. Challenges in heart
transplantation in the era of
COVID-19. Circulation. 2020;141:2048–2051.
31. Kimball P.M., Flattery M., McDougan F., Kasirajan V. Cellular
immunity impaired among patients on left ventricular assist device for
6 months. Ann Thorac Surg. 2008;85:1656–1661.
32. Pagani FD. Right heart failure after left ventricular assist device
placement: medical and surgical management considerations. Cardiol
Clin 2020;38:227–238.
33. Cho SM, Hassett C, Rice CJ, Starling R, Katzan I, Uchino K. What
causes LVAD‐associated ischemic stroke? Surgery, pump thrombosis,
antithrombotics, and infection. ASAIO J 2019;65:775–780.
34. Gorodeski EZ, Goyal P, Cox ZL, Thibodeau JT, Reay R, Rasmusson
K, Rogers JG, Starling RC. Virtual visits for care of patients with
heart failure in the era of COVID‐19: a statement from the Heart Failure
Society of America. J Card Fail 2020;26:448–456.
35. Wang C, Pan R, Wan X, Tan Y, Xu L, RS MI, Choo FN, Tran B, Ho
R, Sharma VK, Ho C. A longitudinal study on the mental health of general
population during the COVID‐19 epidemic in China. Brain Behav Immun
2020;87:40–48.